The liability picture for Olympus endoscope and duodenoscope claims has shifted significantly over the past 12 to 18 months. Major mass tort firms are quietly running a large second wave of case acquisition, driven by recent manufacturer admissions, widespread recalls, and serious FDA interventions targeting internal quality control failures.
These cases currently proceed individually across state and federal courts. While no formalized MDL exists yet, early trials are serving as test cases to evaluate jury response to design defect arguments.
Given the aggressive influx of new filings from top-tier firms, a push for federal consolidation is expected in the near future.
Why Olympus scopes cannot be made safe
Liability anchors strictly on design defect claims, intentionally separating these actions from localized medical malpractice or hospital negligence. Complaints allege that because of sophisticated elevator mechanisms and tiny internal crevices, Olympus scopes are nearly impossible to disinfect under actual hospital reprocessing protocols.
Because biological material and drug-resistant biofilms survive standard sterilization, these instruments become vectors for cross-contamination between patients. They can transmit deadly pathogens, including CRE, E. coli, and MRSA. That structural flaw points strict product liability directly at the manufacturer for putting an inherently dangerous device into circulation, rather than at the facilities using it.
The regulatory triggers driving second-wave acquisition
The recent increase in legal advertising and inventory build-up is a direct result of a series of manufacturer and regulatory failures:
- October 2025 Urgent Field Safety Notice: Olympus issued an Urgent Field Safety Notice admitting that existing reprocessing protocols were insufficient to prevent infection transmission and that new guidelines advised hospitals to use 10X magnification tools to inspect device tips before use.
- January 2026 recall: Olympus issued a formal recall for its original model duodenoscope after continued reports of contamination linked to reprocessing failures.
- March 2026 Health Canada recall: Health Canada recalled specific Olympus valves after identifying cleaning compatibility failures that left devices unable to be adequately sterilized.
- June 2025 FDA import alert: The FDA blocked 58 models of Japan-manufactured Olympus devices from entering the U.S. market, citing severe quality system compliance failures at the manufacturing level.
- January 2025 Class 1 recall: Olympus and the FDA announced a Class 1 recall for the MAJ-891 endoscope accessory, explicitly citing 120 injuries and one death directly linked to reprocessing failures.
Each of these actions hands plaintiffs documented, manufacturer-sourced admissions that prior safety protocols were insufficient. That evidentiary foundation is what allows plaintiff firms to overcome early defense motions before consolidation.
Scale of potential U.S. exposure
U.S. medical facilities perform between 500,000 and 700,000 Endoscopic Retrograde Cholangiopancreatography (ERCP) procedures annually. Olympus controls an estimated 70 to 85 percent of the domestic duodenoscope market. Recent independent surveillance studies and post-market FDA reviews indicate that between 5 and 15 percent of reprocessed, patient-ready scopes test positive for high-concern bacterial organisms.
Translating those contamination rates across half a million annual procedures reveals the scale of the affected patient pool. Superbug infections like CRE carry mortality rates approaching 50 percent once pathogens enter the bloodstream. Survivors endure permanent organ damage, long intensive care unit stays, and catastrophic medical debt.
Intake criteria driving current inventory accumulation
Mass tort firms are using strict intake criteria to separate actionable product liability claims from general post-operative infection claims. The primary criteria include:
- Procedure date: ERCP or related scope diagnostics occurring from 2015 to the present
- Diagnostic window: Documented diagnosis of a superbug, including CRE, MRSA, VRE, E. coli, Pseudomonas aeruginosa, or Klebsiella, sepsis, or acute organ failure within 30 to 90 days following the procedure
- Injury severity: Subsequent hospitalization, intensive care admission, permanent organ damage, or wrongful death resulting directly from the drug-resistant infection
The 60-day mark represents the core medical consensus link for establishing proximate cause between the procedure and the infection.
Why firms need to move before MDL consolidation
The cascade of FDA interventions and manufacturer safety admissions gives plaintiff firms the evidentiary foundation needed to build and defend high-value dockets now. Firms that wait for formal MDL consolidation will enter saturated media markets and face significantly higher acquisition costs. Current conditions favor early capital deployment to secure wrongful death and severe injury claims while pre-consolidation pricing remains at its lowest point.
Atraxia Media converts litigation intelligence into signed clients
If you are looking to scale your Olympus endoscope inventory, Atraxia Media combines deep-dive litigation analysis with a fully in-house, proprietary intake operation that we never outsource. Our trained intake team identifies eligible claimants, screens for the criteria that matter, and signs potential clients that convert. Contact Atraxia Media today to discuss how we can help you build your Olympus endoscope case inventory before the consolidation window closes.